IDEXX Laboratories/$IDXX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About IDEXX Laboratories

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Ticker

$IDXX
Primary listing

Industry

Health Care Equipment & Supplies

Employees

11,000

ISIN

US45168D1046

IDXX Metrics

BasicAdvanced
$43B
49.99
$10.82
1.52
-

What the Analysts think about IDXX

Analyst ratings (Buy, Hold, Sell) for IDEXX Laboratories stock.

Bulls say / Bears say

IDEXX Laboratories raised its annual profit forecast, now projecting earnings between $11.93 and $12.43 per share, up from the previous range of $11.74 to $12.24, indicating strong demand for its pet diagnostics. (reuters.com)
The company reported a 7% year-over-year increase in total quarterly revenues, reaching $976 million, with its companion animal group unit sales rising about 6% to $892 million, showcasing robust growth in its core segment. (reuters.com)
IDEXX Laboratories' stock reached a 52-week high of $546.61, reflecting strong investor confidence and positive market momentum. (investing.com)
IDEXX Laboratories lowered its annual revenue forecast for the third time, now expecting full-year revenue between $3.87 billion and $3.89 billion, down $38 million from previous predictions, due to a decrease in veterinary clinic visits amid inflationary pressures and staffing challenges. (reuters.com)
The company faces challenges in the Asia-Pacific region, including reduced swine testing in China and lower health screening revenues, which have restricted the overall organic growth of its Livestock, Poultry, and Dairy business. (nasdaq.com)
Global macroeconomic conditions, including supply chain disruptions and fluctuations in foreign currency exchange rates, have negatively impacted IDEXX's revenues from international transactions, with the strengthening of the U.S. dollar affecting its financial performance. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

IDXX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

IDXX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IDXX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs